SequelSEC

IMMUCELL CORP /DE/ ICCC

In Vitro & In Vivo Diagnostic Substances · CIK 0000811641 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$30.68M
Fiscal year ended 2026-06-30
Operating income
$3.87M
Fiscal year ended 2026-06-30
Free cash flow
$4.21M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$50.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$5.59Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the In Vitro & In Vivo Diagnostic Substances filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue1.1%0th
FCF margin4.4%89th
Operating margin6.0%85th
Gross margin41.4%22th
Net margin-3.8%77th
R&D / revenue11.0%31th
CapEx / revenue4.5%33th
Long-term debt / equity0.28x33th
Current ratio4.26x60th
Revenue YoY growth4.3%57th

IMMUCELL CORP /DE/ (ICCC) reported revenue of $30.68M and net income of $787.37K for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IMMUCELL CORP /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

IMMUCELL CORP /DE/ income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$30.68M
Cost of revenue$18.31M
Gross profit$12.37M
Operating income$3.87M
Net income$787.37K
Research & development$1.89M
Weighted-average diluted sharesUnavailable
Pretax income$853.61K
Income tax expense$66.23K
Diluted EPSUnavailable
Selling, general & administrative$8.61M
General & administrative$4.27M
Selling & marketing$4.34M

Balance

IMMUCELL CORP /DE/ balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$8.86M
Total assets$46.63M
Current assets$21.08M
Total liabilities$15.26M
Current liabilities$4.44M
Total equity incl. NCI$31.37M
Temporary (mezzanine) equityUnavailable
Inventory$9.08M
Accounts receivable$2.90M
Goodwill$95.56K
Long-term debt$6.80M
Accounts payableUnavailable

Cash flow

IMMUCELL CORP /DE/ cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$5.89M
Capital expenditures$1.68M
Investing cash flow-$1.66M
Financing cash flow-$1.37M
Net change in cash$2.86M
Stock-based compensation$554.76K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.42M

Derived

IMMUCELL CORP /DE/ derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$4.21M
Gross margin40.3%
Operating margin12.6%
FCF margin13.7%
SBC / revenue1.8%
Current ratio4.75x
Revenue YoY growthUnavailable
Net margin2.6%
R&D / revenue6.2%
CapEx / revenue5.5%
Long-term debt / equity0.22x
Effective tax rate7.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ICCC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ACHV AWHL BMRA BZYR CDIO CLDX IDXX IMDX LNTH MYGN NEOG NTLA

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.